^
Association details:
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
Title:

Primary resistance to first- and second-generation ALK inhibitors in a non-small cell lung cancer patient with coexisting ALK rearrangement and an ALK F1174L-cis-S1189C de novo mutation: A case report

Published date:
11/23/2022
Excerpt:
Pathological analysis of bronchoscopy biopsy tissue confirmed lung adenocarcinoma….The presence of EML4-ALK gene fusion and an ALK exon 23 F1174L and S1189C mutation was identified by targeted next-generation sequencing...The patient received crizotinib (250 mg, BID) as first-line targeted therapy for approximately 2.5 months...progressive disease (PD) was diagnosed according to chest CT...
DOI:
https://doi.org/10.3389/fphar.2022.1060460